Introduction
============

*MYCN proto-oncogene bHLH transcription factor* (*MYCN*) amplification and 1p36 deletion are important factors associated with poor prognosis in neuroblastoma ([@b1-mmr-19-01-0345]--[@b3-mmr-19-01-0345]), one of the most types of infant malignancy ([@b4-mmr-19-01-0345]). *MYCN* amplification, which leads to *MYCN* overexpression, has been reported in 18--38% of cases of neuroblastoma and in a panel of neuroblastoma cell lines ([@b3-mmr-19-01-0345],[@b5-mmr-19-01-0345]--[@b9-mmr-19-01-0345]). As a developmentally-regulated gene, *MYCN* is highly expressed in dorsal root ganglia, sympathetic chain ganglia and the spinal cord in the human fetus during the development of the sympathetic nervous system at 8.5 weeks of gestation ([@b9-mmr-19-01-0345]). In addition, the chromosome 1p36 locus is frequently deleted in neuroblastoma cell lines ([@b10-mmr-19-01-0345]). *Chromodomain helicase DNA binding protein 5, calmodulin binding transcription activator 1, kinesin family member 1B β, castor zinc finger 1* and *microRNA* (*miR*)*−34a* have been analyzed as the strongest candidate tumor suppressor genes at the 1p36 locus in neuroblastoma ([@b11-mmr-19-01-0345],[@b12-mmr-19-01-0345]).

c-MYB proto-oncogene transcription factor (c-Myb) has been reported to be associated with cell growth and proliferation in neuroblastoma ([@b13-mmr-19-01-0345]). On induction by retinoic acid, c-*myb* and *MYCN* expression levels decrease during the differentiation stage of neuroblastoma cells ([@b14-mmr-19-01-0345]--[@b18-mmr-19-01-0345]). In humans, c-*myb, MYB proto-oncogene like 2* (B-*myb*) and *MYB proto-oncogene like 1* (A-*myb*) belong to the *myb* gene family, and contain highly-conserved N-terminal domains ([@b19-mmr-19-01-0345]). The functional orthologs B-*myb* and *Drosophila melanogaster-myb* (Dm-*myb*) share essential conserved functions required for cell proliferation, whereas the paralogous genes, A-*myb* and c-*myb*, have acquired novel functions ([@b20-mmr-19-01-0345]). The Dm-Myb protein complex is directly involved in DNA replication and binds to amplification-control-element-on-3 (*ACE3*) and replication origin-β in a site-specific manner ([@b21-mmr-19-01-0345]), necessary for chorion gene amplification on the third chromosome in *Drosophila* ovarian follicle cells ([@b22-mmr-19-01-0345]).

The Dm-myb complex regulates the expression of developmentally-regulated genes ([@b23-mmr-19-01-0345]). Additionally, it has been proposed that this complex may be involved in the activation or repression of transcription and DNA replication, depending on the presence of E2F transcription factor 1 (E2F1) or E2F transcription factor 2 (E2F2) with other particular cofactors, respectively. *Drosophila* lethal ([@b3-mmr-19-01-0345]) malignant brain tumor \[D-L(3)mbt\] protein has also been associated with the Myb-MuvB repressor complex ([@b23-mmr-19-01-0345]).

The human homolog of *D-l(3)mbt, L3MBTL1 histone methyl-lysine binding protein* (*L3MBTL1*), is expressed in cancer cell lines and a variety of normal human tissues ([@b24-mmr-19-01-0345]). L3MBTL1, a candidate tumor suppressor in del(20q12) myeloid disorders, is required for normal progression of the replication fork, and interacts with the minichromosome maintenance complex component 2--7, cell division cycle 45 and proliferating cell nuclear antigen components of the DNA replication machinery ([@b25-mmr-19-01-0345]).

Chromatin licensing and DNA replication factor 1 (hCdt1) is an essential factor of the pre-replication complex and is inhibited by geminin (GMNN) protein to prevent re-replication during the S, G~2~ and M phases of the cell cycle ([@b26-mmr-19-01-0345]). *GMNN* and *hCdt1* are overexpressed in tumors and a variety of cancer-derived cell lines ([@b27-mmr-19-01-0345]--[@b29-mmr-19-01-0345]).

MYCN transcriptionally activates the *p53* tumor suppressor gene to induce apoptosis ([@b30-mmr-19-01-0345]); however, MYCN suppresses the *cyclin dependent kinase inhibitor 1A* (*p21*) gene, resulting in anti-apoptotic activity of neuroblastoma ([@b31-mmr-19-01-0345]). *MYCN* overexpression sensitizes *MYCN*-amplified neuroblastoma cells to apoptosis via the induction of p53 ([@b32-mmr-19-01-0345]). In addition, E2F-regulated B-*myb* and c-*myb* expression are elevated by apoptotic stimuli, causing neuronal death ([@b33-mmr-19-01-0345]).

In the present study, potential c-Myb target genes, and the effect of c-*myb* RNA interference (RNAi) on *MYCN* expression and amplification in neuroblastoma were investigated. For this, a plasmid vector-mediated RNAi method with a short hairpin RNA (shRNA) directed against c-*myb* mRNA was used in *MYCN*-amplified neuroblastoma cell lines. The present study demonstrated that c-*myb* may induce the expression of *E2F1* and *L3MBTL1* and that *E2F1* may be associated with the induction of *MYCN*, B-*myb, p21* and *hCdt1* expression, in addition to the repression of *GMNN*. In addition, the results demonstrated that *MYCN* gene copy number was increased following treatment with c-*myb* RNAi. These findings revealed that c-*myb* is involved in controlling *MYCN* expression and amplification in *MYCN*-amplified neuroblastoma cell lines. Following c-*myb* RNAi treatment, *L3MBTL1* expression was completely silenced, whereas *GMNN* was upregulated; the results indicate G~2~/M arrest. Consequently, the present study demonstrated that the *MYCN* gene may be amplified during S phase, which may occur via a replication-based mechanism.

Materials and methods
=====================

### Sequence comparison

The DNA sequences encompassing the *D. melanogaster-ACE3* element and that upstream of human *MYCN* were compared using the LFASTAn alignment program (version 2; bioinfo.hku.hk/services/analyseq/cgi-bin/lfastan_in.pl). The DNA sequences of *D. melanogaster*-chorion gene cluster (GenBank accession no. X02497.1) and *Homo sapiens*-chromosome 2 genomic contig, including the *MYCN* gene (NCBI reference sequence NT_005334.16; region, 8493966-11135164) were downloaded from the NCBI website ([ncbi.nlm.nih.gov](ncbi.nlm.nih.gov)).

### Transcription factor binding site search

Transcription factor binding sites upstream (−1,021 to −143), including the enhancer and proximal promoter of *MYCN* gene were investigated using the TFSEARCH program (version 1.3; [cbrc.jp/research/db/TFSEARCH.html](cbrc.jp/research/db/TFSEARCH.html)). In addition, the location information of the regulatory transcription factor binding sites in the promoters of all genes investigated in the present study was obtained from Qiagen, Inc. (Valencia, CA, USA) as predicted by Text Mining Application (SABioscience Corporation; Qiagen, Inc.) and the University of California Santa Cruz (UCSC) Genome Browser ([sabiosciences.com/chipqpcrsearch.php?app=TFBS](sabiosciences.com/chipqpcrsearch.php?app=TFBS)).

### Cell culture

Kelly (no. ACC 355), IMR32 (no. ACC 165), SIMA (no. ACC 164), MHH-NB-11 (no. ACC 157) and SH-SY5Y (no. ACC 209) cell lines were purchased from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig, Germany). Kelly, SIMA and MHH-NB-11 cells were cultured in RPMI-1640 (cat. no. FG1215; Biochrom AG; Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (cat. no. S0113; FBS; Biochrom AG; Merck KGaA), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. In addition, the culture medium of MHH-NB-11 cells included 1X non-essential amino acids. IMR32 cells were cultured in RPMI-1640 (Biochrom AG; Merck KGaA) supplemented with 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 1X non-essential amino acids. SH-SY5Y cells were cultured in Dulbecco\'s modified Eagle\'s medium (cat. no. FG0415; DMEM; Biochrom AG; Merck KGaA) supplemented with 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were incubated at 37°C in a humidified atmosphere containing 5% CO~2~.

### Fluorescence in situ hybridization (FISH)

FISH was performed as previously described ([@b3-mmr-19-01-0345],[@b34-mmr-19-01-0345]). In FISH experiments, *MYCN* gene (2p24)/Chromosome 2 α-Satellite (red/green; cat. no. PONC0224; Qbiogene, Inc.; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1p36/Chr 1 SE (Poseidon probe red/green, cat. no. KB-10705; Kreatech Diagnostics Corp., Amsterdam, LG, Netherlands) and 1p36/1q25 (Vysis probe orange/green, cat. no. 32-231004; Abbott Pharmaceutical Co. Ltd., Lake Bluff, IL, USA) probes were used.

Neuroblastoma cells were seeded into 25-cm^2^ tissue culture flasks and grown in culture medium specific for each cell line (please see '*Cell culture*' section for the characteristics of each growth medium) in a humidified atmosphere containing 5% CO~2~ at 37°C. The cells were detached with trypsin-EDTA (Biochrom AG; Merck KGaA) and incubated with 80 µl colcemid (Biological Industries, Kibbutz Beit Haemek, Israel) in a tube containing 5 ml culture medium in a 37°C water bath for 30 min. Following centrifugation at 300 × g for 10 min at room temperature, the cell pellets were incubated with 8 ml hypotonic solution (0.075 M) (Biochrom AG; Merck KGaA) in a 37°C water bath for 30 min. For the fixation of the cell pellets, 5 ml fresh Carnoy\'s solution (3:1 Methanol:Glacial Acetic Acid; Merck KGaA) was used for 2--3 min at room temperature followed by centrifugation at 300 × g for 10 min (repeated five times).

The homogenized cells were dropped onto slides, and a 2X SSC (AppliChem GmbH, Darmstadt, Germany)/0.5% NP-40 (AppliChem) mixture was used for washing the slides in a 37°C water bath for 30 min. The slides were dehydrated in an ethanol (AppliChem) series of 70, 85 and 96%, respectively. The double-stranded DNAs on the slides were denatured in 70% formamide (AppliChem)/2X SSC (AppliChem) at 70°C for 2 min (5 min for Abbott/Vysis 1p36 probe). The denaturation of probes was performed in a 96°C water bath for 5 min (5 and 10 min at 75°C for Vysis and Poseidon 1p36 probes, respectively). The DNAs were hybridized with the probes via overnight incubation at 37°C in a hybridization box. The 0.5X SSC (AppliChem)/0.1% SDS (Honeywell Riedel-de Haën AG, Seelze, Germany), 1X PBD including NP40 (AppliChem) and Tween 20 (Santacruz Biotechnology, Inc., Dallas, Texas, USA) and 70% ethanol (AppliChem), respectively, were used for washing the slides after hybridization overnight. Cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole II (DAPI II; cat. no. 30-804841; Abbott Pharmaceutical Co. Ltd.) suspended in an antifade solution.

FISH slides were analyzed under an epifluorescence microscope (magnification, ×100; Nikon Eclipse E600, Nikon Corporation, Tokyo, Japan) equipped with DAPI, FITC, rhodamine and triple band-pass filter sets. FISH images from interphase nuclei and metaphase spreads were captured using a high-sensitivity monochrome charge-coupled device camera, which was integrated with a Macintosh computer and processed with MacProbe imaging software (version 4.0, PSI Scientific Systems, League City, TX, USA).

In FISH analyses, 2 red and 2 green signals for *MYCN* and internal control per diploid genome were considered normal; 3--5 red signals vs. 2 green signals per diploid genome were scored as a low copy number of the *MYCN* gene; 6--10 red signals vs. 2 green signals per diploid genome were scored as an intermediate copy number of *MYCN* gene, whereas \>10 red signals vs. 2 green signals per diploid genome indicate high copy number of *MYCN*.

For 1p36 and the internal control, 2 orange/red and 2 green signals per diploid genome were considered normal. Only 1 orange/red signal vs. ≥2 green signals per diploid genome was classified as a 1p36 deletion. A total of 2 orange/red signals vs. 3 green signals per diploid genome and so forth (representing at least one more signal number of control than that of the 1p36 probe) were considered to indicate an imbalance in 1p36 copy number; 3 orange/red and 3 green signals per diploid genome were classified as a 1p36-3/3 balanced alteration.

### DNA extraction

Kelly, SIMA, IMR32, MHH-NB-11 and SH-SY5Y cells were seeded into 75-cm^2^ tissue culture flasks and grown in a culture medium until cells reached near-confluence in a humidified atmosphere containing 5% CO~2~ at 37°C. Genomic DNA was extracted using phenol:chloroform:isoamyl alcohol (25:24:1, respectively), pH 8.0 (cat. no. A0889.0500; AppliChem GmbH, Darmstadt, Germany) as previously described ([@b35-mmr-19-01-0345]).

### cDNA synthesis

Kelly, SIMA, IMR32, MHH-NB-11 and SH-SY5Y cells were seeded into 24-well plates at a density of 4×10^4^ cells in 0.75 ml culture medium per well and grown in a culture medium until cells reached near-confluence in a humidified atmosphere containing 5% CO~2~ at 37°C. First-strand cDNAs were synthesized directly from adherent cultured cells, without requiring RNA purification or RNase H digestion steps, using the FastLane Cell cDNA kit (cat. no. 215011; Qiagen, Inc.) according to the manufacturer\'s protocol. The procedure of this kit involves four steps: i) removing extracellular contaminants, ii) performing cell lysis and RNA stabilization, iii) eliminating genomic DNA and iv) producing the first-strand cDNA via reverse transcription. This kit has been optimized for use particularly in real-time, two-step reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The genomic DNA from the FastLane lysate was eliminated using gDNA Wipeout Buffer at 42°C for five min. The lysate was placed immediately on ice. The reverse-transcription reaction was performed at 42°C for 30 min; later reverse transcriptase enzyme was inactivated for finishing reaction at 95°C for three min according to the manufacturer\'s protocol.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

In neuroblastoma cell lines, the expression levels of c-*myb* and potential target genes, and *MYCN* gene copy number compared with hypoxanthine phosphoribosyltransferase 1 (*HPRT1*) and *p53* reference genes, respectively, were determined via qPCR on a LightCycler^®^ 2.0 instrument (Roche Diagnostics, Basel, Switzerland). Relative quantitative qPCR experiments were performed using the LightCycler^®^ TaqMan^®^ Master kit (cat. no. 04535286001; Roche Applied Science, Penzberg, Germany) with prevalidated hydrolysis probes, Universal ProbeLibrary Set, Human (cat. no. 04683633001; Roche Applied Science) and primers according to the manufacturer\'s protocol.

Probe and primer sets were designed using the web-based ProbeFinder software (version 2.40) via the UPL assay design center ([www.universalprobelibrary.com](www.universalprobelibrary.com)). Primer pairs were synthesized by Gene Link, Inc. (Hawthorne, NY, USA). NCBI accession numbers, probe/primer sets and amplicon sizes are presented in [Table I](#tI-mmr-19-01-0345){ref-type="table"}.

In the calculation of both mRNA expression levels and gene copy number in neuroblastoma cell lines, the following equations (∆Cp method) were used: Presumed as *E*=2, ∆*Cp*=(*Cp~target~-Cp~reference~*) and *R*=2^−∆*Cp*^ ([@b36-mmr-19-01-0345]). A heatmap for visualizing gene expression and *MYCN* gene copy number within neuroblastoma cell lines was produced using Heatmapper software ([www.heatmapper.ca](www.heatmapper.ca)) ([@b37-mmr-19-01-0345]).

In addition, *MYCN* copy number and gene expression levels from *MYCN*-amplified neuroblastoma cell lines prior to- and post-treatment with c-*myb* RNAi as normalized to the Cp values of target and reference genes of SH-SY5Y cells, were determined using the following equation (ΔΔCp method): Presumed as *E*=2 $$R1 = 2^{- \Delta\Delta Cp} = 2^{- {\lbrack{\Delta Cp_{\textit{target}}(\textit{sample\ -\ control}) - \Delta Cp_{\textit{ref}}(\textit{sample\ -\ control})}\rbrack}}$$.

In the efficiency-corrected (dilution) method, to determine the slope (*S*), the standard curves were produced between mean Cp values and logarithms (logs) of five serial starting template concentrations (ranging from 2--32 ng) using Excel (v. 2; Turkish, Home and Student version/initial release date; 07/17/2007, Microsoft Corporation, Redmond, WA, USA). *E* and *R2* values were calculated using the following equations: $$E_{\textit{target}\textit{or}\textit{ref}} = 10^{\lbrack - 1/S\rbrack}\text{and} R2 = \frac{\left( E_{\textit{target}} \right)^{\Delta Cp_{\textit{target}}{(\textit{control\ -\ sample})}}}{\left( E_{\textit{ref}} \right)^{\Delta Cp_{\textit{ref}}{(\textit{control\ -\ sample})}}}$$.

### RNAi

In the *MYCN*-amplified Kelly, SIMA, IMR32 and MHH-NB-11 cell lines, c-*myb* mRNA expression was dysregulated using a specific shRNA-expressing pre-made plasmid DNA vector (custom-made psiRNA-h7SKneo G1 kit; cat. no. ksirna3-n21; InvivoGen, San Diego, CA, USA) according to the manufacturer\'s protocols.

A shRNA insert in the double-stranded RNA structure, which specifically targeted c-*myb* mRNA (NCBI accession no. M15024.1), was designed using InvivoGen siRNA wizard software (version 2.4; [sirnawizard.com](sirnawizard.com)) and later ligated into the psiRNA-h7SKneo G1 expression vector. Pre-made plasmid DNA vectors (InvivoGen) expressing shRNAs for enhanced green fluorescent protein (EGFP) or irrelevant genes served as shRNA controls. Plasmid vectors containing the sequences of shRNA targeting c-*myb* mRNA and control shRNAs were transformed into *E*. *coli* LyoComp GT116 strain (InvivoGen).

For *Spe*I enzyme digestion and DNA sequencing, plasmid DNA was extracted from transformed cells using the High Pure Plasmid Isolation kit (Roche Applied Science, Penzberg, Germany) according to the manufacturer\'s protocols. Plasmid DNA vector expressing the shRNA directed against c-*myb* mRNA and EGFP control vector were cut with the *Spe*I restriction enzyme (cat. no. ER1252; Thermo Fisher Scientific, Inc.) at a concentration of 10 U/µl (final concentration 0.5 U/µl) incubated in a 37°C water bath for 14 h and imaged following agarose gel electrophoresis (1%) stained with ethidium bromide. DNA Marker II was used for genomic DNA analysis (cat. no. SM0351; Fermentas; Thermo Fisher Scientific, Inc.). The shRNA sequences of c-*myb* and EGFP vectors were confirmed by plasmid DNA sequencing (Macrogen, Inc., Seoul, Korea) in both directions using forward (OL559) and reverse (OL408) primers. Primer sequences: OL559 primer (forward) 5′-CGATAAGTAACTTGACCTAAGTG-3′ and OL408 primer (reverse) 5′-GCGTTACTATGGGAACATAC-3′; c-*myb* shRNA, oligo 1 (forward) 5′-ACCTCGGTTATCTGCAGGAGTCTTCATCAAGAGTGAAGACTCCTGCAGATAACCTT-3′ and oligo 2 (reverse) 5′-CAAAAAGGTTATCTGCAGGAGTCTTCACTCTTGATGAAGACTCCTGCAGATAACCG-3′; EGFP shRNA, oligo 1 (forward) 5′-ACCTCGCAAGCTGACCCTGAAGTTCACCACCTGAACTTCAGGGTCAGCTTGCTT-3′ and oligo 2 (reverse) 5′-CAAAAAGCAAGCTGACCCTGAAGTTCAGGTGGTGAACTTCAGGGTCAGCTTGCG-3′.

For stable transfection, purified plasmid DNA was isolated in intermediate quantities using the Genopure Plasmid Midi kit (Roche Applied Science). LyoVec reagent (InvivoGen) was used for the transfection of plasmid DNAs (5--6 µg) into *MYCN*-amplified neuroblastoma cell lines \[cell number per well (6-well plate): 8×10^5^\]. Selection and maintenance of transfected cells expressing the neomycin-resistance (*neo*) gene were performed with G418 treatment (InvivoGen) at a concentration of 500--800 µg/ml for 4 weeks.

### Statistical analysis

Statistical differences were determined using a one-tailed Wilcoxon signed-rank test. For two-tailed analysis, Spearman\'s (*r*~s~) and Pearson\'s (*r*) coefficients were used to investigate correlation; correlation coefficients (*r, r*~s~) were evaluated according to the classified criteria as low (0.00--0.24), moderate (0.25--0.49), strong (0.50--0.74) and very strong (0.75--1.00) ([@b39-mmr-19-01-0345]). P\<0.05 was considered to indicate a statistically significant difference. All analyses were performed using SPSS software version 11.0 (SPSS, Inc., Chicago, IL, USA).

Results
=======

### Sequence upstream of human MYCN gene shares \~44% sequence identity with a region encompassing ACE3, upstream of chorion genes in D. melanogaster

It has been determined that promoter and enhancer regions are located \~200 and 800 bp upstream of *MYCN*, respectively, and have been reported to be responsible for basal and cell type-specific expression in a variety of murine and human cell lines ([@b40-mmr-19-01-0345]). In addition, the similar organization of the origin elements and replicators, including *ACE3* and *DHFR*, from *Drosophila*, mammals, *Tetrahymena* and *Sciara* has been reviewed previously ([@b41-mmr-19-01-0345]). In normal human cells, amplified DNA has not been observed at frequencies greater than 1/10^8^, and MYCN expression has been reported to be limited in normal human adult tissues ([@b42-mmr-19-01-0345],[@b43-mmr-19-01-0345]).

Taken together, previous reports have suggested that certain *trans*-acting and epigenetic factors may serve important roles in the transcriptional and/or epigenetic control of *MYCN* expression and amplification. It was hypothesized that the DNA sequences of upstream *cis*-regulatory elements of amplifiable genes in a variety of organisms may be evolutionarily conserved, at least in part. The present study thus investigated the degree of sequence similarity between sequence upstream of the human *MYCN* gene and the *ACE3* element controlling chorion gene amplification in *D. melanogaster* ([@b44-mmr-19-01-0345]).

Initially, the DNA sequences encompassing *MYCN* upstream and *ACE3* were compared using the LFASTAn program ([Fig. 1A](#f1-mmr-19-01-0345){ref-type="fig"}). The results revealed that sequences upstream of the human *MYCN* gene (−1,021 to −143; bases 2,466,909 to 2,467,787), including the enhancer and proximal promoter, share a 43.545% sequence identity in an overlap of 914 nucleotides with a DNA fragment (bases 14 to 884) spanning the *D. melanogaster ACE3* sequence. This result suggested that the expression and/or amplification mechanisms of developmentally-regulated genes may be conserved among various organisms during the evolutionary process.

### Putative c-Myb and E2F1 binding sites detected in the enhancer and proximal promoter located upstream of MYCN

Enhancer (−980 to −860), inhibition (−860 to −797) and promoter (−279 to +108) regions of *MYCN* were previously identified in IMR32 cells ([@b45-mmr-19-01-0345]). Additionally, *MYCN* expression mediated by this enhancer is induced at higher levels within IMR32 cells than in HeLa cells, indicating cell type-specific enhancement of *MYCN* expression. Recently, it was reported that the DNA binding motif of MYB (c-Myb) is specifically enriched in low-complexity transcription factor binding site (TFBS)-clustered regions ([@b46-mmr-19-01-0345]), which suggested that c-Myb may contribute to cell type-specific transcriptional regulation.

To identify the putative transcription factor binding sites upstream of *MYCN*, the TFSEARCH program was employed ([Fig. 1B](#f1-mmr-19-01-0345){ref-type="fig"}). A total of two c-Myb and three E2F1 binding sites were identified in the enhancer and proximal promoter located upstream of *MYCN*, which shares partial sequence identity with a region encompassing *ACE3*. The bioinformatics data analysis of the present study indicated that c-Myb and E2F1 may be involved in the expression of the *MYCN* gene in neuroblastoma cells.

### MYCN amplification status, 1p36 alterations and ploidy level determined by FISH analysis in neuroblastoma cell lines

To determine *MYCN* amplification status and 1p36 alterations in neuroblastoma cells ([Fig. 2](#f2-mmr-19-01-0345){ref-type="fig"}), interphase nuclei and metaphase spreads were analyzed using FISH. The degree of *MYCN* amplification (\>10 copies per nucleus) was notably high in Kelly, SIMA, MHH-NB-11 and IMR32 cells ([Table II](#tII-mmr-19-01-0345){ref-type="table"}); however, the fluorescence signal intensity of nuclei for each *MYCN*-amplified cell line differed ([Fig. 2B](#f2-mmr-19-01-0345){ref-type="fig"}). The SH-SY5Y cell line lacking *MYCN* amplification most commonly included three copies (93.1%) of *MYCN* ([Table II](#tII-mmr-19-01-0345){ref-type="table"} and [Fig. 2B](#f2-mmr-19-01-0345){ref-type="fig"}). Our recent study demonstrated that three copies of *MYCN* in SH-SY5Y may be due to an unbalanced translocation involving the *MYCN* locus at 2p24 ([@b34-mmr-19-01-0345]). The FISH analysis of metaphase spreads typically demonstrated homogeneously staining regions (HSRs) in Kelly, MHH-NB-11, and IMR32 cells, and double minutes in SIMA cells ([Fig. 2C](#f2-mmr-19-01-0345){ref-type="fig"}). In addition, the ploidy levels of all cell lines were determined ([Fig. 2C](#f2-mmr-19-01-0345){ref-type="fig"}).

In the present study, IMR32 exhibited the highest degree of 1p36 deletion, whereas the percentage was markedly low in other neuroblastoma cell lines ([Table II](#tII-mmr-19-01-0345){ref-type="table"} and [Fig. 2D](#f2-mmr-19-01-0345){ref-type="fig"}). The 1p36 imbalance was higher in SIMA and MHH-NB-11 compared with SH-SY5Y, Kelly and IMR32 cells ([Table II](#tII-mmr-19-01-0345){ref-type="table"} and [Fig. 2D](#f2-mmr-19-01-0345){ref-type="fig"}). 1p36-3/3 balanced alterations were observed at a higher percentage in Kelly cells compared with other cell lines and were negatively correlated with 1p36 deletion ([Table II](#tII-mmr-19-01-0345){ref-type="table"} and [Fig. 2D](#f2-mmr-19-01-0345){ref-type="fig"}).

Taken together, FISH analyses revealed that all the neuroblastoma cell lines analyzed in the present study contained aneuploid cell clones. Additionally, *MYCN*-amplified cell lines exhibited *MYCN* amplification and at least one 1p36 alteration as structural chromosome aberrations, whereas SH-SY5Y cells exhibited 1p36 imbalance, but no *MYCN* amplification.

### c-myb expression, candidate target gene expression and MYCN gene copy number determined by qPCR in neuroblastoma cell lines

The candidate c-Myb target genes were selected using published literature on neuroblastoma tumor biology and gene amplification mechanisms, together with predicted binding site data for transcription factors in gene promoters (SABiosciences Text Mining Application and UCSC Genome Browser).

The present study investigated the associations between c-*myb* expression, candidate target gene expression, *MYCN* gene copy number and 1p36 alterations. *MYCN* gene copy number and the expression levels \[*MYCN*, c-*myb*, B-*myb*, A-*myb, E2F1, E2F2, p53, p21, cyclin-dependent kinase inhibitor 1B* (*p27*), *hCdt1, GMNN, cyclin dependent kinase 2* (*CDK2*) and *L3MBTL1*\] were determined in neuroblastoma cell lines compared with the reference genes, *p53* and *HPRT1*, via qPCR prior to c-*myb* RNAi ([Table III](#tIII-mmr-19-01-0345){ref-type="table"} and [Fig. 3A](#f3-mmr-19-01-0345){ref-type="fig"}). The expression levels of *MYCN* and B-*myb* were notably higher compared with those of *E2F1, hCdt1, GMNN, p27, CDK2, p21, L3MBTL1* and c-*myb* in *MYCN*-amplified cell lines ([Table III](#tIII-mmr-19-01-0345){ref-type="table"} and [Fig. 3B](#f3-mmr-19-01-0345){ref-type="fig"}).

A-*myb, E2F2* and *p53* were not expressed in any of the five neuroblastoma cell lines ([Table III](#tIII-mmr-19-01-0345){ref-type="table"}). *E2F2* has been analyzed as a candidate tumor suppressor gene located at the 1p36 locus, which is deleted in 25% of tumors and 87% of cell lines in neuroblastoma ([@b2-mmr-19-01-0345],[@b10-mmr-19-01-0345]). According to FISH analysis, the 1p36 deletion was observed at a high percentage only in the IMR32 cell line ([Table II](#tII-mmr-19-01-0345){ref-type="table"}), suggesting that *E2F2* may be epigenetically repressed in cell lines lacking the 1p36 deletion.

Using qPCR, *MYCN* gene copy number per haploid genome compared with the reference gene, *p53*, was notably high in Kelly cells (1,488.87 copies); however, 82.14, 80.45 and 74.54 copies were detected in IMR32, SIMA and MHH-NB-11 cells, respectively. The copy number for SH-SY5Y cells was 0.63 ([Fig. 3C](#f3-mmr-19-01-0345){ref-type="fig"}).

Pearson\'s correlation coefficient analysis revealed a notably positive significant correlation between 1p36-3/3 balanced alteration and *MYCN* gene copy number (*r*=0.99, P\<0.001; [Tables II](#tII-mmr-19-01-0345){ref-type="table"} and [III](#tIII-mmr-19-01-0345){ref-type="table"}, and [Fig. 4A](#f4-mmr-19-01-0345){ref-type="fig"}), which requires further cytogenetic examination in *MYCN*-amplified neuroblastoma cells bearing the 1p36-3/3 alteration. Our recent study identified a large interstitial deletion at 1q25-q41 in Kelly cell line predominantly possessing the 1p36-3/3 alteration in metaphase ([@b34-mmr-19-01-0345]), suggesting that loss of heterozygosity of one or more tumor suppressor genes located in this region may contribute to a significant increase in *MYCN* gene copy number.

The mRNA expression levels of *MYCN* and c-*myb* genes declined within 3 h of treatment with retinoic acid of neuroblastoma cell lines ([@b16-mmr-19-01-0345]). Statistical analysis revealed a significant positive correlation between c-*myb* and *MYCN* expression ([Table III](#tIII-mmr-19-01-0345){ref-type="table"} and [Fig. 4B](#f4-mmr-19-01-0345){ref-type="fig"}). This finding suggested that there may be an association between the expression of c-*myb* and *MYCN* genes in neuroblastoma cells.

### Correlations between 1p36 alterations and expression of c-myb, B-myb and p21 genes

Previous reports have revealed that c-Myb and B-Myb facilitate G~2~/M progression via the direct upregulation of *cyclin B1* in normal, embryonic stem and cancer cells ([@b47-mmr-19-01-0345]--[@b49-mmr-19-01-0345]), whereas depletion of p21 causes chromosome segregation and cytokinesis defects in HCT116, HeLa and SAOS-2 cells ([@b50-mmr-19-01-0345]). Statistical analyses of the present study revealed a significant negative correlation between *p21* expression and 1p36 imbalance (*r*~s~=−1.00, P\<0.001; [Fig. 4C](#f4-mmr-19-01-0345){ref-type="fig"}); however, a significant positive correlation between c-*myb* expression and 1p36-3/3 alteration (*r*=0.96, P\<0.02; [Fig. 4D](#f4-mmr-19-01-0345){ref-type="fig"}) in neuroblastoma cell lines was observed ([Tables II](#tII-mmr-19-01-0345){ref-type="table"} and [III](#tIII-mmr-19-01-0345){ref-type="table"}). In addition, B-*myb* expression and 1p36-3/3 alteration were negatively correlated with 1p36 deletion (*r*~s~=−0.82, P=0.089; *r*~s~=−0.87, P=0.054; [Tables II](#tII-mmr-19-01-0345){ref-type="table"} and [III](#tIII-mmr-19-01-0345){ref-type="table"}; [Fig. 4E and F](#f4-mmr-19-01-0345){ref-type="fig"}). All statistical data suggested that c-*myb*, B-*myb* and *p21* genes may serve an important role against the genomic instability of chromosome 1p in neuroblastoma cells.

### c-myb and E2F1 may be involved in controlling MYCN expression and amplification

The present study employed RNAi against c-*myb* mRNA. A *c-myb*-specific shRNA sequence was designed and ligated into a plasmid DNA vector. Following transformation, plasmid DNA was transfected into *MYCN*-amplified Kelly, IMR32, SIMA and MHH-NB-11 neuroblastoma cell lines. To generate stably transfected cell lines, the cells expressing c-*myb* shRNA were selected using G418. The presence of c-*myb*-specific and EGFP-specific shRNAs in plasmid vectors prior to transfection was confirmed by *Spe*I enzyme digestion and DNA sequencing.

RNAi reduced c-*myb* mRNA expression by 95.58, 77.79, 86.42 and 88.89% in Kelly, SIMA, MHH-NB-11 and IMR32 cells, respectively ([Fig. 5A](#f5-mmr-19-01-0345){ref-type="fig"}). *MYCN*/*p53* DNA copy number ratios from *MYCN*-amplified cell lines were determined using the ∆∆Cp method ([@b36-mmr-19-01-0345]) as normalized to the Cp values of *MYCN* and *p53* genes from the SH-SY5Y control cell line in pre- and post-c-*myb* RNAi groups. These results were compared with those of the efficiency corrected (dilution) method ([@b36-mmr-19-01-0345],[@b38-mmr-19-01-0345]) in Kelly, SIMA and IMR32 cells. The results of the present study revealed that *MYCN* gene copy numbers increased by 115.85, 71.70, 85.31 and 53.69% following c-*myb* RNAi treatment of Kelly, SIMA, IMR32 and MHH-NB-11 cells, respectively ([Fig. 5B](#f5-mmr-19-01-0345){ref-type="fig"}). The findings of the present study suggested that c-*myb* may be involved in controlling *MYCN* amplification.

The expression levels of *MYCN*, c-*myb, E2F1, hCdt1*, B-*myb, GMNN, p21* and *L3MBTL1* genes in Kelly, SIMA, MHH-NB-11 and IMR32 cell lines as normalized to the Cp values of target and reference (*HPRT1*) genes of the control SH-SY5Y cell line were determined pre- and post-c-*myb* RNAi. The mRNA expression level of each gene was presented as the mean of related expression levels from the four aforementioned *MYCN*-amplified cell lines ([Fig. 6](#f6-mmr-19-01-0345){ref-type="fig"}). The expression level of *MYCN* was moderately decreased by 33.99±5.78% following treatment with c-*myb* RNAi in *MYCN*-amplified cell lines, while *E2F1* expression was downregulated by 86.66±8.40%. These results suggested that c-*myb* may be involved in the induction of *E2F1* and *MYCN* expression, potentially via putative c-Myb binding sites in their promoters.

However, the c-*myb* may also be indirectly associated with *MYCN* expression via the upregulation of *E2F1* ([Fig. 7A and B](#f7-mmr-19-01-0345){ref-type="fig"}). *E2F1* may be involved in activation of the *MYCN* promoter, possibly via putative E2F1 binding sites ([Fig. 1B](#f1-mmr-19-01-0345){ref-type="fig"}). It was previously reported that E2F1-3 proteins activate the *MYCN* promoter via E2F binding sites in Kelly and IMR32 cells ([@b51-mmr-19-01-0345]). Taken together, the findings of the present study indicate that c-*myb* and *E2F1* may be involved in controlling *MYCN* expression and amplification in *MYCN*-amplified neuroblastoma cells.

### E2F1 may contribute to hCdt1, p21 and B-myb gene expression in MYCN-amplified neuroblastoma cells

In HCT116 cells, the *hCdt1* promoter is activated by E2F1 ([@b52-mmr-19-01-0345]). In addition, E2F1 induces *p21* transcription by directly binding to the proximal promoter of *p21* via a p53-independent mechanism in NIH3T3 cells ([@b53-mmr-19-01-0345]), but also transactivates the B-*myb* promoter in SAOS-2 cells ([@b54-mmr-19-01-0345]).

In the present study, the mRNA expression level of *hCdt1* declined by 37.48±12.45% following c-*myb* RNAi in *MYCN*-amplified neuroblastoma cell lines ([Fig. 6](#f6-mmr-19-01-0345){ref-type="fig"}). In addition, a significant positive correlation was identified between *E2F1* and *hCdt1* expression post-c-*myb* RNAi. *p21* was also expressed; however, the *p53* transcript was not detected in neuroblastoma cells ([Table III](#tIII-mmr-19-01-0345){ref-type="table"}). Following c-*myb* RNAi treatment, *p21* expression was downregulated by 92.51±4.94% in *MYCN*-amplified neuroblastoma cell lines ([Fig. 6](#f6-mmr-19-01-0345){ref-type="fig"}). Additionally, B-*myb* expression was downregulated by 82.49±6.28% following c-*myb* RNAi treatment ([Fig. 6](#f6-mmr-19-01-0345){ref-type="fig"}).

These results suggest that *E2F1* may induce *hCdt1, p21* and B-*myb* expression, potentially via putative E2F1 binding sites in the promoters of these genes in *MYCN*-amplified neuroblastoma cells ([Fig. 7](#f7-mmr-19-01-0345){ref-type="fig"}).

### MYCN gene is amplified during S phase, possibly via a replication-based mechanism: GMNN expression is upregulated following c-myb RNAi treatment in MYCN-amplified neuroblastoma cell lines

*GMNN* transcription is induced by E2F1-4 transcription factors via the RB transcriptional corepressor 1 (Rb)/E2F signaling pathway ([@b52-mmr-19-01-0345]). The present study reported *GMMN* upregulation; however, *E2F1* mRNA expression was downregulated following c-*myb* RNAi treatment ([Fig. 6](#f6-mmr-19-01-0345){ref-type="fig"}). *GMNN* was also upregulated following *E2F1* RNAi treatment (data not shown) in *MYCN*-amplified neuroblastoma cell lines.

The mRNA expression levels of *GMNN* are higher in the S and G~2~/M phases compared with the G~1~/S transition of the cell cycle ([@b28-mmr-19-01-0345],[@b52-mmr-19-01-0345]). In addition, Rb serves an important role in the repression of *GMNN* via intragenic E2F sites during G~1~ ([@b55-mmr-19-01-0345]). The promoter of *Rb* contains a putative E2F1 binding site, suggesting that E2F1 may directly regulate the *Rb* promoter. Therefore, *E2F1* may be associated with the repression of *GMNN* expression via the induction of Rb in *MYCN*-amplified neuroblastoma cells ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}). These findings indicate that *MYCN* gene copy number increased during S phase, while neuroblastoma cells progress toward G~2~/M phase following c-*myb* RNAi treatment ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}).

### c-myb RNAi causes silencing of L3MBTL1 expression in MYCN-amplified cell lines, indicating G2/M arrest

Inhibition of *L3MBTL1* mRNA expression leads to G~2~/M arrest in a variety of cancerous and normal human cells ([@b25-mmr-19-01-0345]). In the present study, *L3MBTL1* expression was silenced in *MYCN*-amplified cell lines following treatment with c-*myb* RNAi ([Fig. 6](#f6-mmr-19-01-0345){ref-type="fig"}). In addition, bioinformatics analysis demonstrated that the promoter of *L3MBTL1* harbors a putative binding site for c-Myb, but not for E2F. These results suggest that c-*myb* may induce *L3MBTL1* expression, possibly via a putative c-Myb binding site identified in the promoter of *L3MBTL1* in *MYCN*-amplified neuroblastoma cells ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}).

In addition, *L3MBTL1* expression was highly downregulated by *E2F1* RNAi in Kelly, SIMA and IMR32 cells (data not shown), suggesting that E2F1 may transactivate the promoter of c-*myb* in neuroblastoma cells, similar to human glioblastoma cells ([@b56-mmr-19-01-0345]). However, the c-*myb* promoter does not include any putative E2F binding sites.

In conclusion, the findings of the present study suggested that *L3MBTL1* may be a potential c-Myb target gene. In addition, similar to *GMNN* upregulation, the silencing of *L3MBTL1* expression following c-*myb* RNAi treatment indicates that *MYCN* gene copy number increased prior to G~2~/M arrest in *MYCN*-amplified neuroblastoma cell lines ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}). Taken together, it is concluded that *MYCN* gene is amplified during S phase, potentially via a replication-based mechanism.

Discussion
==========

Neuroblastoma is a common pediatric solid tumor derived from the primitive cells of the sympathetic nervous system ([@b57-mmr-19-01-0345]). *MYCN* amplification is an important factor associated with poor prognosis in neuroblastoma ([@b5-mmr-19-01-0345]). *MYCN* is amplified in 18--38% of reported cases ([@b3-mmr-19-01-0345],[@b5-mmr-19-01-0345]--[@b7-mmr-19-01-0345]) and in a panel of neuroblastoma cell lines ([@b8-mmr-19-01-0345]). The mRNA expression levels of *MYCN* and c-*myb* decline within 3 h following treatment with retinoic acid in neuroblastoma cell lines ([@b16-mmr-19-01-0345]). However, the expression and amplification mechanisms of *MYCN* require further study.

The present study investigated the potential target genes of c-Myb and the effects of c-*myb* RNAi on *MYCN* expression and amplification. *MYCN* gene copy number and mean expression levels of *MYCN*, c-*myb, E2F1, hCdt1*, B-*myb, GMNN, p21* and *L3MBTL1* genes were determined in *MYCN*-amplified neuroblastoma cell lines, which were normalized to their counterparts from the SH-SY5Y control cell line in pre- and post-c-*myb* RNAi treatment. To compare with those of the ∆∆Cp method, *MYCN* gene copy numbers of Kelly, SIMA and IMR32 cells were also determined using the dilution method.

The ∆∆Cp method revealed that *MYCN* gene copy number increased by 115.85, 71.70, 85.31 and 53.69% in Kelly, SIMA, IMR32 and MHH-NB-11 cells, respectively, following c-*myb* RNAi treatment. The dilution method also revealed that *MYCN* gene copy number was increased in Kelly (336.49%), SIMA (20.58%) and IMR32 (76.83%) cells normalized to target and reference Cp values of the control SH-SY5Y cell line. However, PCR amplification efficiency (*E*) values out of range 1.95--2.05 in the dilution method led to notable differences in the *MYCN* gene copy numbers compared with those obtained from the ∆∆Cp method, particularly for Kelly and SIMA. Using the dilution method, *E* values \>2.0, which are unexpected in theory, have been practically observed ([@b36-mmr-19-01-0345]). Taken together, ∆∆Cp and dilution methods demonstrated an increase in *MYCN* gene copy number following c-*myb* RNAi treatment, suggesting that c-*myb* may be involved in controlling *MYCN* amplification in *MYCN*-amplified neuroblastoma cells.

Previously, Beall *et al* ([@b21-mmr-19-01-0345]) reported that the protein product of *D. melanogaster-myb* gene, which is closely associated with the vertebrate *myb* gene family (including A-*myb*, B-*myb* and c-*myb*) ([@b19-mmr-19-01-0345],[@b20-mmr-19-01-0345]), is required for chorion gene amplification *in trans*. However, it was proposed that a Dm Myb-MuvB repressor complex, including D-L(3)mbt protein, may be involved in the repression of transcription and DNA replication ([@b23-mmr-19-01-0345]). The paralogous human gene, c-*myb*, has acquired novel functions not possessed by the Dm-*myb* gene ([@b20-mmr-19-01-0345]). L3MBTL1, a human homolog of the D-l(3)mbt protein, interacts with the DNA sliding clamp and other proteins, forming a replicative helicase complex, and is required for progression of the replication fork ([@b25-mmr-19-01-0345]). Loss of *L3MBTL1* mRNA expression is an indicator of G~2~/M arrest ([@b25-mmr-19-01-0345]). The present study reported that *L3MBTL1* mRNA expression was silenced, whereas *MYCN* gene copy number increased following c-*myb* RNAi treatment of *MYCN*-amplified neuroblastoma cell lines. Taken together with published data, the findings of the present study suggest that *L3MBTL1* may act as a guard against arrest or abnormal forms of replication forks during *MYCN* amplification. Furthermore, the present study indicated that *MYCN* gene copy number was increased prior to G~2~/M arrest.

Statistical analysis revealed a notably significant positive correlation between c-*myb* and *MYCN* expression levels in neuroblastoma cells ([Table III](#tIII-mmr-19-01-0345){ref-type="table"}). Furthermore, the expression levels of *MYCN* were moderately decreased in *MYCN*-amplified neuroblastoma cells following c-*myb* RNAi treatment. In addition, bioinformatics analysis demonstrated that the enhancer and promoter of *MYCN* include putative c-Myb binding sites. The results of the present study suggest that *MYCN* may be a potential target gene of c-Myb and that c-*myb* may be associated with the induction of *MYCN* expression, potentially via the promoter and/or enhancer regions of *MYCN*. Upon induction by retinoic acid in human neuroblastoma cells, the mRNA expression levels of c-*myb* and *MYCN* decrease within 3 h ([@b14-mmr-19-01-0345]--[@b18-mmr-19-01-0345]).

Following treatment with c-*myb* RNAi, the mRNA expression levels of *E2F1* and *MYCN* decreased, whereas the *MYCN* gene copy number increased in *MYCN*-amplified neuroblastoma cells. Bioinformatics analyses demonstrated that the *MYCN* promoter includes putative E2F1 binding sites, while that of *E2F1* harbors c-Myb binding sites. These results suggested that *E2F1* may be a potential target gene of c-Myb; and c-*myb* gene is involved in the induction of *E2F1* expression potentially via a putative c-Myb-binding site in the *E2F1* promoter. As with c-*myb, E2F1* may also be associated with the induction of *MYCN* expression, potentially via E2F1 binding sites in the *MYCN* promoter. Our preliminary studies demonstrated that *MYCN* expression is downregulated by *E2F1* RNAi in Kelly and IMR32 cells (data not shown). E2F1-3 have been reported to activate the proximal promoter of *MYCN* gene in Kelly and IMR32 cells ([@b51-mmr-19-01-0345]). Collectively, these findings suggested that c-*myb* and *E2F1* may be involved in controlling *MYCN* expression and amplification via the promoter and/or enhancer regions of *MYCN*.

In the present study, B-*myb* and *p21* were observed to be downregulated following treatment with c-*myb* RNAi. In addition, the expression levels of B-*myb* and *p21* decreased following *E2F1* RNAi treatment in Kelly, SIMA, MHH-NB-11 and IMR32 cell lines (data not shown). Bioinformatics data revealed that the *p21* promoter includes putative E2F1 binding sites without a c-Myb binding site (Qiagen, Inc.). These results indicated that *E2F1* may be associated with the induction of B-*myb* and *p21* mRNA expression, possibly via putative E2F1 binding sites in their respective promoters. A direct interaction causing S-phase arrest between the E2F1 transcription factor and the proximal promoter of *p21* was previously demonstrated in NIH3T3 cells ([@b53-mmr-19-01-0345]), and E2F1 transactivates the B-*myb* promoter in SAOS-2 cells ([@b54-mmr-19-01-0345]).

E2F1 transcriptionally activates the Tp73 tumor suppressor that induces p53-responsive genes and apoptosis ([@b58-mmr-19-01-0345]). The expression level of p21 protein is increased in the IGR-N-91 neuroblastoma cell line (containing mutated p53) infected with TAp73α recombinant adenovirus; this leads to G~1~ arrest via a p53-independent signaling pathway ([@b59-mmr-19-01-0345]). In *MYCN*-amplified neuroblastoma, MYCN transactivates miR-*17-5p*, which in turn accelerates cell cycle progression and protects cells from apoptosis via the downregulation of p21 and BIM, respectively ([@b60-mmr-19-01-0345]). MYCN overexpression sensitizes *MYCN*-amplified neuroblastoma cells to apoptosis via the induction of p53 ([@b32-mmr-19-01-0345]). Additionally, enforced MYCN expression causes a significant reduction in cell viability via the apoptosis signaling pathway in SY5Y and SK-N-AS cell lines lacking *MYCN* amplification ([@b61-mmr-19-01-0345]).

Furthermore, Guglielmi *et al* ([@b18-mmr-19-01-0345]) reported that the mRNA expression levels of pro-apoptotic *E2F1* and *Tp73* are increased without modulating *Tp53* mRNA expression, due to the inhibition of miR-9, miR-20a and miR-92a by upregulated *MYCN* expression in SK-N-AS cells. It was concluded that *MYCN* may be required during the activation of neuroblastoma differentiation to induce apoptosis in undifferentiated cells. In addition, Guglielmi *et al* ([@b18-mmr-19-01-0345]) reported that cell death was not observed following treatment with retinoic acid of *MYCN*-silenced LAN-5 cells (\~40%) harboring *MYCN* amplification, whereas control LAN-5 cells did exhibit retinoic acid-induced apoptosis.

In the present study, *p21* was identified to be transcribed in neuroblastoma cells, whereas *p53* mRNA was not expressed under normal conditions. Taken together, the results suggested that c-*myb* and *E2F1* may contribute to the sensitization of *MYCN*-amplified cells to apoptosis by inducing *MYCN* overexpression that indirectly activates E2F1 protein, which in turn upregulates p73 and p21 in neuroblastoma ([@b18-mmr-19-01-0345],[@b32-mmr-19-01-0345],[@b53-mmr-19-01-0345],[@b58-mmr-19-01-0345],[@b62-mmr-19-01-0345]--[@b64-mmr-19-01-0345]). That is, *MYCN* amplification may be partially controlled via *E2F1*-induced G~1~/S arrest and apoptosis in *MYCN*-amplified neuroblastoma cells ([Fig. 7A](#f7-mmr-19-01-0345){ref-type="fig"}).

In a previous study, c-Myc expression was reported to be upregulated in 5--15% of the p53^−/−^ mice cells in all the tissues examined, whereas \<1% of p53^+/+^ cells express detectable levels of c-Myc protein ([@b65-mmr-19-01-0345]). Apoptotic p53^−/−^ cells characteristically exhibit atypical chromosome morphology, abnormally amplified centrosomes, aneuploidy, c-*myc* gene amplification and elevated c-Myc protein levels, indicating that c-Myc-overexpressing cells undergo apoptosis and numerous genetically aberrant cells are eliminated by p53-independent apoptosis *in vivo* ([@b65-mmr-19-01-0345]).

The apoptotic control mechanism proposed in the present study for *MYCN*-amplified neuroblastoma cells via c-*myb* and *E2F1*-associated *MYCN* overexpression can explain why the *MYCN* gene copy number increases despite reductions in mRNA expression levels of *MYCN* following c-*myb* RNAi treatment. In cisplatin-resistant UKF-NB-4 neuroblastoma cells with *MYCN* amplification, *MYCN* expression levels increased although no significant change was observed in the *MYCN* copy number following cisplatin treatment, suggesting that alterations in *MYCN* expression may not always be associated with variations in *MYCN* copy number ([@b66-mmr-19-01-0345]). *MYCN* expression may be controlled by mechanisms independent from *MYCN* copy number under discrete conditions in neuroblastoma cell lines. Additional *MYCN* gene copies may also repress their own transcription. By analyzing genome-wide data of the regions that vary in copy number in humans and certain model organisms, it has been reported that genes with varied copy number in copy number variation (CNV) regions are expressed at lower and more variable levels than genes mapped elsewhere; CNVs also exert a global influence on the transcriptome ([@b67-mmr-19-01-0345]). Alterations in copy number of CNV regions can influence gene expression by several mechanisms, including physical dissociation of the transcription unit from its *cis*-acting regulators, modification of transcriptional control by altering chromatin structure and position, and perturbation of transcript structure ([@b67-mmr-19-01-0345]). Additional copies of *MYCN* may also impair *MYCN* transcription due to steric hindrance for access to specific transcription factories, as previously described in a general hypothesis regarding extra copies of any gene ([@b67-mmr-19-01-0345],[@b68-mmr-19-01-0345]).

In the present study, FISH analyses of the metaphase spreads from neuroblastoma cells revealed near-diploid (2n±), hyperhaploid (n+) and near-polyploid (3n-, 3n+ and 4n-) aneuploidies. In addition, qPCR experiments revealed the expression of *CDK2* and *MYCN* genes in neuroblastoma cells. Centrosomes with multiple copies, abnormal structure and function have frequently been observed in the most common types of human malignant tumors and tumor-derived cell lines ([@b69-mmr-19-01-0345]). Hyperactive *CDK2* and *MYCN* overexpression induce centrosome amplification and chromosomal instability, resulting in aneuploidy and formation of micronuclei (a precursor to aneuploidy) in *p53*^−/−^ mouse embryonic fibroblasts and neuroblastoma cells following DNA damage, respectively ([@b70-mmr-19-01-0345],[@b71-mmr-19-01-0345]). However, enhanced expression of *MYCN* without DNA damage in a neuroblastoma cell line did not cause centrosome hyperamplification and micronuclei formation ([@b71-mmr-19-01-0345]).

Sugihara *et al* ([@b71-mmr-19-01-0345]) predicted an increase in a fraction of the cell population with DNA contents of 8N, resulting from centrosome hyperamplification with DNA replication caused by the failure of cell division following DNA damage. However, Sugihara *et al* ([@b71-mmr-19-01-0345]) also identified that the fraction of MYCN-EGFP cells with 8N did not increase compared with that of vector-EGFP cells, suggesting that *MYCN* overexpression may contribute to the apoptotic elimination of neuroblastoma cells with genomic DNA amplification and formation of micronuclei. Similarly, the apoptotic cells of p53^−/−^ mice contain abnormally amplified centrosomes, aneuploidy, high levels of c-Myc expression and gene amplification ([@b65-mmr-19-01-0345]).

Statistical analyses revealed that B-*myb* and *p21* expression are negatively correlated with 1p36 deletion and imbalance, respectively (*r*~s~=−0.82, P=0.089; *r*~s~=−1.00, P\<0.001). Conversely, a significant positive correlation was identified between c-*myb* expression and 1p36-3/3 alteration in neuroblastoma cells (*r*=0.96, P\<0.02), suggesting that c-*myb*, B-*myb* and *p21* may serve a role against genomic instability in chromosome 1p. p21 deficiency leads to abnormal centriole replication ([@b72-mmr-19-01-0345]), whereas p21 overexpression rescues *p53*-deficient human tumor cells from endoreduplication and aneuploidy/polyploidy ([@b73-mmr-19-01-0345],[@b74-mmr-19-01-0345]).

Following c-*myb* RNAi treatment, *L3MBTL1* expression was silenced in *MYCN*-amplified Kelly, SIMA, IMR32 and MHH-NB-11 neuroblastoma cell lines in the current study, indicating that *L3MBTL1* may be a potential c-Myb target gene. The c-*myb* gene may be involved in the induction of *L3MBTL1* expression, possibly via a putative c-Myb-binding site in the *L3MBTL1* promoter. In certain cancer cell lines, including SW480, the *L3MBTL1* transcript is markedly reduced ([@b24-mmr-19-01-0345]). In addition, *L3MBTL1* has been considered to be a candidate tumor suppressor gene in myeloid malignancies associated with 20q12 deletions ([@b25-mmr-19-01-0345]). Furthermore, depletion of *L3MBTL1* causes replicative stress, DNA breaks, activation of the DNA damage response and genomic instability in human cells, and leads to G~2~/M arrest in a variety of cancerous and normal human cells ([@b25-mmr-19-01-0345]). Considering the published literature, the results of the present study suggested that *L3MBTL1* may act as a tumor suppressor gene in neuroblastoma cells. Together, the results indicated that *MYCN* gene copy number increased prior to G~2~/M arrest, potentially following the loss of *L3MBTL1* mRNA expression on treatment with c-*myb* RNAi.

*GMNN* expression was also increased along with *MYCN* gene copy number following c-*myb* RNAi treatment in *MYCN*-amplified neuroblastoma cell lines in the current study. In addition, a positive correlation was identified between *GMNN* expression and *MYCN* gene copy number. These results suggest that *GMNN* upregulation may lead to a switch from genomic DNA replication to *MYCN* amplification by suppressing re-replication. Similarly, in the follicle cells of *Dm geminin* mutant ovaries, it was reported that a switch from general genomic endoreplication to the amplification cycles occurs during stage 10B ([@b75-mmr-19-01-0345]). The present study also reported a partially identical region of \~44% between DNA fragments encompassing the sequence upstream of human *MYCN* gene and *ACE3* controlling chorion gene amplification in *D. melanogaster*. This finding suggested that the expression and/or amplification mechanisms of developmentally-regulated genes may be conserved among different organisms during the evolutionary process. As with c-*myb* RNAi, *E2F1* RNAi caused the upregulation of *GMNN* expression in *MYCN*-amplified neuroblastoma cell lines (data not shown). *GMNN* expression is transcriptionally repressed by the activation of Rb throughout G~1~ ([@b55-mmr-19-01-0345]). In view of the literature and the findings of the present study, it can be hypothesized that the *E2F1* gene may be indirectly involved in controlling *GMNN* expression via transcriptional activation of the *Rb* promoter.

In addition, the results of the present study suggested that *E2F1* contributed to the induction of *hCdt1* expression in *MYCN*-amplified neuroblastoma cells. Additionally, it was identified that an *E2F1* RNAi experiment in SIMA, as with c-*myb* RNAi, caused the downregulation of *hCdt1* expression (data not shown). The promoter of *hCdt1* is activated by E2F1 in HCT116 cells ([@b52-mmr-19-01-0345]). Taken together, the results suggested that *E2F1* may be implicated in controlling the expression of *GMNN* and *hCdt1* genes throughout the cell cycle ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}).

The mRNA expression levels of *GMNN* are upregulated in S and G~2~/M phases ([@b28-mmr-19-01-0345],[@b52-mmr-19-01-0345]), followed by the degradation of geminin protein via APC/C^Cdc20^ and mitotic spindle checkpoint during metaphase and early anaphase ([@b26-mmr-19-01-0345],[@b76-mmr-19-01-0345]) in human cells. In addition, loss of *L3MBTL1* transcript leads to G~2~/M arrest ([@b25-mmr-19-01-0345]). B-Myb and c-Myb contribute to the G~2~/M transition in normal human cells, embryonic stem cells and cancer cells ([@b47-mmr-19-01-0345]--[@b49-mmr-19-01-0345]).

In conclusion, the results of the present study revealed that c-*myb* and *E2F1* genes may be involved in controlling *MYCN* expression and amplification in *MYCN*-amplified neuroblastoma cells. As described in the model mechanism proposed in [Fig. 7A](#f7-mmr-19-01-0345){ref-type="fig"}, c-*myb* and *E2F1* may contribute to the apoptotic elimination of *MYCN*-amplified cells via the induction of *MYCN* overexpression that indirectly activates E2F1-induced apoptosis. However, it remains to be determined whether c-myb and E2F1 are involved in the induction of apoptosis in *MYCN*-amplified neuroblastoma cell lines. In addition, c-*myb* may be associated with the upregulation of *L3MBTL1* ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}). Furthermore, *L3MBTL1* may be considered as candidate tumor suppressor gene in neuroblastoma cells. The results of the present study also indicated that the cell cycle is stopped or delayed in the G~2~/M transition of the *MYCN*-amplified neuroblastoma cells following c-*myb* RNAi treatment ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}). Therefore, it is concluded that *MYCN* gene is amplified during S phase, possibly via a replication-based mechanism ([Fig. 7B](#f7-mmr-19-01-0345){ref-type="fig"}).

In drug-resistant Chinese hamster sublines and two neuroblastoma cell lines, SK-N-BE(2) and IMR-32, the HSRs containing *DHFR* and *MYCN*, respectively, were previously demonstrated to undergo relatively rapid and synchronous replication prior to the midpoint of the S phase as observed by tritiated thymidine radioautography ([@b77-mmr-19-01-0345]). However, there is no clear evidence on whether *MYCN* is amplified during S phase. Neuroblastoma cell lines harbor a head-to-tail tandem array in the direct orientation of DNA segments containing *MYCN* gene in amplified regions ([@b78-mmr-19-01-0345]), suggesting that *MYCN* amplification may arise from a mechanism other than those involving breakage-fusion-bridge cycles that produce inverted duplications ([@b79-mmr-19-01-0345]). Numerous replication-based mechanisms for the formation of *MYCN* or general gene amplification have been proposed ([@b12-mmr-19-01-0345],[@b41-mmr-19-01-0345],[@b78-mmr-19-01-0345],[@b80-mmr-19-01-0345]--[@b84-mmr-19-01-0345]).

Aygun ([@b84-mmr-19-01-0345]) recently reported that long inverted repeats (LIRs) are significantly associated with 5′ and 3′ boundary regions of the amplicon units containing *MYCN* gene in 14 neuroblastoma cell lines and 42 other primary solid tumors, whose genomic data were obtained from the catalogue of somatic mutations in cancer (COSMIC database; [cancer.sanger.ac.uk/cosmic/](cancer.sanger.ac.uk/cosmic/)) ([@b85-mmr-19-01-0345]). In addition, Aygun ([@b86-mmr-19-01-0345]) previously reported a significant association between LIRs and the breakpoint regions of gross deletions in human cancers and inherited diseases. Numerous LIRs inside and outside the *MYCN* amplicon units were identified, suggesting that LIRs may extrude hairpin and cruciform structures in single- and double-stranded DNA during replication, respectively ([@b84-mmr-19-01-0345]). The hairpin structure can form at an interrupted LIR on leading and lagging strand templates simultaneously during replication ([@b87-mmr-19-01-0345]). The hairpin and cruciform conformations can cause replication fork stalling ([@b87-mmr-19-01-0345],[@b88-mmr-19-01-0345]). In addition, a mean microhomology of 5.18 bp (range, 2--14 bp) between DNA sequences of 150 bp encompassing the 5′ and 3′ boundaries of the *MYCN* amplicon units has been reported ([@b12-mmr-19-01-0345],[@b84-mmr-19-01-0345]). Microhomology between 0 and 15 bp indicates nonhomologous end joining, microhomology-mediated end joining, microhomology-mediated break-induced replication or fork stalling and template switching mechanisms ([@b83-mmr-19-01-0345],[@b89-mmr-19-01-0345],[@b90-mmr-19-01-0345]). Consequently, the findings of the present study indicated that a replication-based mechanism involving LIRs in a microhomology-dependent manner may generate *MYCN* amplification during S phase. Therapeutic targeting of *MYCN* amplification during S phase may improve the prognosis of neuroblastoma patients.
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![Sequence comparison between *MYCN* upstream and *ACE3*, and transcription factor binding sites in *MYCN* upstream. (A) A 1,020 bp DNA sequence (top; bases 1--1,020) encompassing *ACE3* from *Drosophila melanogaster* chorion gene cluster and a DNA sequence of \~65 kb (bottom) containing *MYCN* (bases 2,416,201 to 2,481,180) from human chromosome 2 genomic contig were compared using the LFASTAn program. (B) Using the TFSEARCH program, putative c-Myb and E2F1 binding sites upstream (−1,021 to −143) of human *MYCN* gene were detected. *MYCN, MYCN proto-oncogene bHLH transcription factor*; *ACE3, amplification-control-element-on-3*; c-Myb, transcriptional activator Myb; E2F1, E2F transcription factor 1.](MMR-19-01-0345-g02){#f1-mmr-19-01-0345}

![*MYCN* amplification and 1p36 alterations from interphase and metaphase in neuroblastoma cell lines. (A) Neuroblastoma cells were harvested for FISH experiments (magnification, ×40). (B) *MYCN* amplification status of interphase nuclei was determined by FISH. (C) Modal number, hsr and dmin from metaphase in neuroblastoma cell lines are demonstrated. (D) 1p36 alterations from metaphase and interphase in neuroblastoma cell lines are presented. Magnification for B-D, ×100. *MYCN, MYCN proto-oncogene bHLH transcription factor*; *ACE3, amplification-control-element-on-3*; FISH, fluorescence *in situ* hybridization; del, deletion; dmin, double minute; hsr, homogeneously staining region; imb, imbalance; SE, satellite enumeration.](MMR-19-01-0345-g03){#f2-mmr-19-01-0345}

![Expression of potential c-Myb target genes and *MYCN* gene copy number in neuroblastoma cell lines. (A) Heat map visualizing the mRNA expression of 10 genes and *MYCN* gene copy number (*MYCN*-DNA) from neuroblastoma cell lines compared with reference genes, *HPRT1* and *p53*, respectively. The color key represents the column Z-score of gene expression levels and copy numbers. Dark pink indicates the lowest gene expression or copy number and dark green indicates the highest gene expression or copy number. (B) Expression levels of *MYCN* and B-*myb* as compared with reference *HPRT1*; (C) *MYCN* gene copy number as compared with reference *p53* in neuroblastoma cell lines (see also [Table III](#tIII-mmr-19-01-0345){ref-type="table"}). *MYCN, MYCN proto-oncogene bHLH transcription factor*; B-*myb, MYB proto-oncogene like 2*; *E2F1, E2F transcription factor 1*; *hCdt1, chromatin licensing and DNA replication factor 1*; *GMNN, geminin*; *p27, cyclin-dependent kinase inhibitor 1B*; *CDK2, cyclin dependent kinase 2*; *p21, cyclin-dependent kinase inhibitor 1A*; *L3MBTL1, L3MBTL1 histone methyl-lysine binding protein*; *c-Myb, transcriptional activator Myb*; *HPRT1, hypoxanthine phosphoribosyltransferase 1*.](MMR-19-01-0345-g04){#f3-mmr-19-01-0345}

![Scatter plots for correlations of gene expressions and genomic alterations identified in neuroblastoma cell lines. The correlations of (A) *MYCN* copy number and 1p36-3/3 alteration, (B) c-*myb* and *MYCN* expression, (C) *p21* expression and 1p36 imbalance, (D) 1p36-3/3 alteration and c-*myb* expression, (E) B-*myb* expression and 1p36 deletion, (F) 1p36 deletion and 1p36-3/3 alteration and (G) *MYCN* copy number and *GMNN* expression were presented. The scatter plots were produced using Excel. *MYCN, MYCN proto-oncogene bHLH transcription factor*; *c-Myb, transcriptional activator Myb*; B-*myb, MYB proto-oncogene like 2*; *GMNN, geminin*; *p21, cyclin-dependent kinase inhibitor 1A*.](MMR-19-01-0345-g05){#f4-mmr-19-01-0345}

![The effect of c-*myb* RNAi treatment on *MYCN* gene copy number. (A) Interference rate of c-*myb* mRNA was presented as compared with shRNA controls in *MYCN*-amplified neuroblastoma cell lines. The expression levels of c-*myb* mRNA were determined pre- and post-c-*myb* RNAi treatment of Kelly, SIMA, MHH-NB-11 and IMR32 cell lines, as normalized to the Cp values of target and reference genes of the SH-SY5Y control cell line. R-value was calculated using the mean Cp ± standard error of duplicate or triplicate experiments in case of discordant results. (B) *MYCN*/*p53* DNA copy number ratios were determined by the delta-delta Cp method pre- and post-c-*myb* RNAi treatment as compared with shRNA control in *MYCN*-amplified neuroblastoma cell lines. Data are expressed as mean Cp ± standard error of the mean from ≥6 independent experiments. \*P\<0.05, Wilcoxon signed rank test (one-tailed). shRNA, short hairpin RNA; *c-myb, transcriptional activator myb*; RNAi, RNA interference; *MYCN, MYCN proto-oncogene bHLH transcription factor*.](MMR-19-01-0345-g06){#f5-mmr-19-01-0345}

![Alterations in potential c-Myb target gene expression and *MYCN* gene copy number following treatment with c-*myb* RNAi. *MYCN* gene copy number and expression levels of c-*myb* and potential target genes (B-*myb, p21, hCdt1, E2F1, L3MBTL1, GMNN* and *MYCN*) were calculated in *MYCN*-amplified neuroblastoma cell lines as normalized to the Cp values of target and reference genes of SH-SY5Y control cell line using the delta-delta Cp method ([@b36-mmr-19-01-0345]). \*\*Data are expressed as mean variation (%) ± standard error of the mean from Kelly, SIMA, MHH-NB-11 and IMR32 cell lines (n=4). \*P\<0.05; Wilcoxon signed rank test (one-tailed). shRNA, short hairpin RNA; RNAi, RNA interference; B-*myb, MYB proto-oncogene like 2*; *p21, cyclin-dependent kinase inhibitor 1A*; *hCdt1, chromatin licensing and DNA replication factor 1*; *c-myb, transcriptional activator myb*; *E2F1, E2F transcription factor 1*; *L3MBTL1, L3MBTL1 histone methyl-lysine binding protein*; *GMNN, geminin*; *MYCN, MYCN proto-oncogene bHLH transcription factor*.](MMR-19-01-0345-g07){#f6-mmr-19-01-0345}

![Involvement of c-*myb* and *E2F1* in the expression and amplification of *MYCN*. (A) Model mechanism indicates the possible contribution of c-*myb* and *E2F1* genes in the apoptotic elimination of *MYCN*-amplified neuroblastoma (MNA NB) cells via the upregulation of *MYCN* expression. *MYCN* overexpression indirectly activates the E2F1-induced apoptosis signaling pathway, potentially by inhibiting miR-20a and miR-92a, which prevent upregulation of *E2F* genes. (B) Flow schema showing the alterations in *MYCN* gene copy number and expression of c-*myb, E2F1* and potential target genes following treatment with c-*myb* RNAi in *MYCN*-amplified neuroblastoma cell lines. \*Spearman\'s correlation coefficient, two-tailed (*r*~s~=1.0, P\<0.01). miR, microRNA; RNAi, RNA interference. c-*myb, transcriptional activator myb*; *MYCN, MYCN proto-oncogene bHLH transcription factor*; *E2F1, E2F transcription factor 1*; p-73, tumor protein p73; p21, cyclin-dependent kinase inhibitor 1A; *L3MBTL1, L3MBTL1 histone methyl-lysine binding protein*; B-*myb, MYB proto-oncogene like 2*; *hCdt1, chromatin licensing and DNA replication factor 1*; Rb, RB transcriptional corepressor; *GMNN, geminin*.](MMR-19-01-0345-g08){#f7-mmr-19-01-0345}

###### 

Probe and primer pairs used for quantitative polymerase chain reaction.

  A, mRNA                                                                                                        
  --------------------------- ---------------------------- -------------------------- -------------------------- ------------------------
  A-*myb* BC101186.1          2, 04684982001               aagcaagtggctgggaca         ctccttttaagaatgcgcttg      75
  B-*myb* X13293.1            26, 04687574001              gccagagacttccggacttt       cccgagaagcagaagagga        68
  c-*myb* M15024.1            62, 04688619001              agctgcatgtgtggttctgt       tgctcctaatgtcaaccgaga      72
  *MYCN* BC002712.2           55, 04688520001              cctcttcatcatcttcatcatctg   ccacaaggccctcagtacc        68
  *E2F1* BC050369.2           5, 04685024001               ctgggtcaacccctcaag         tccaagaaccacatccagtg       75
  *E2F2* BC053676.1           68, 04688678001              gccttgacggcaatcact         ggacaaggccaacaagagg        93
  *CDK2* BC003065.2           50, 04688112001              cagaatctccagggaataggg      cctcctgggctgcaaata         104
  *GMNN* AF067855.1           53, 04688503001              ccagaggttcaccattcagtc      aactggcagaagtagcagaaca     72
  *hCdt1* AB053172.1          10, 04685091001              agcaggtgcttctccatttc       gcggagcgtctttgtgtc         117
  *L3MBTL1* BC039820.1        82, 04689054001              ttccttcttcttgcttctcca      agcgcagggaataccagag        72
  *p21* BC000275.1            70, 04688937001              agctgctcgctgtccact         ccgaggcactcagaggag         112
  *p53* AB082923.1            12, 04685113001              ccctttttggacttcaggtg       aggccttggaactcaaggat         85
  *p27* BC001971.1            1, 04684974001               cgggttaactcttcgtggtc       agatgtcaaacgtgcgagtg       130
  *HPRT1* BC000578.2          73, 04688961001              cgagcaagacgttcagtcct       tgaccttgatttattttgcatacc   102
                                                                                                                 
  **B, DNA**                                                                                                     
                                                                                                                 
  **NCBI accession number**   **Probe catalogue number**   **Right primer (5′-3′)**   **Left primer (5′-3′)**    **Amplicon size (nt)**
                                                                                                                 
  *MYCN* Y00664.1             36, 04687949001              ggcctttagggtcagacaga       tgaccagggtcatgcaacta       60
  *p53* U94788.1              23, 04686977001              ctctagccaagcttccatcc       ttcagctcgggaaaatcg         88

B-*myb, MYB proto-oncogene like 2*; A-*myb, MYB proto-oncogene like 1*; *c-Myb, transcriptional activator Myb*; *MYCN, MYCN proto-oncogene bHLH transcription factor*; *E2F1, E2F transcription factor 1*; *E2F2, E2F transcription factor 2*; *CDK2, cyclin dependent kinase 2*; *GMNN, geminin*; *hCdt1, chromatin licensing and DNA replication factor 1*; *L3MBTL1, L3MBTL1 histone methyl-lysine binding protein*; *p21, cyclin-dependent kinase inhibitor 1A*; *p27, cyclin-dependent kinase inhibitor 1B*; *HPRT1, hypoxanthine phosphoribosyltransferase 1*.

###### 

*MYCN* amplification and 1p36 alterations in neuroblastoma cell lines^[a](#tfn2-mmr-19-01-0345){ref-type="table-fn"}^.

              *MYCN* amplification (%)   1p36 alterations (%)^[b](#tfn3-mmr-19-01-0345){ref-type="table-fn"}^                                          
  ----------- -------------------------- ---------------------------------------------------------------------- ----- -------- ------- ------- ------- -------
  SH-SY5Y     3.8                        96.2                                                                   0.0     0.0    67.1      2.8     0.4   28.4
  Kelly       0.0                          0.0                                                                  0.0   100.0      2.4   49.8      0.1   11.4
  SIMA        0.0                          1.5                                                                  3.4     95.1     7.4     0.9     0.4   91.1
  MHH-NB-11   0.0                          0.0                                                                  0.0   100.0      0.4     3.4     0.0   95.7
  IMR32       0.0                          0.0                                                                  0.0   100.0      5.0     0.6   85.9      8.5

Percentage of *MYCN* amplification and 1p36 alterations from 260 and 500 interphases/metaphases using the fluorescence *in situ* hybridization method in cell lines, respectively, was determined.

1p36 alteration other than 3/3-balanced, deletion and imbalance is not presented.

Spearman\'s correlation coefficient, 1p36-3/3 vs. 1p36 deletion (*r*~s~=−0.87, P=0.054). *MYCN* amplification was characterized as normal ([@b2-mmr-19-01-0345]), low ([@b3-mmr-19-01-0345]--[@b5-mmr-19-01-0345]), intermediate ([@b6-mmr-19-01-0345]--[@b10-mmr-19-01-0345]) and high (\>10). *MYCN, MYCN proto-oncogene bHLH transcription factor*.

###### 

Expression of candidate c-Myb target genes and *MYCN* gene copy numbers in neuroblastoma cell lines.

  A, mRNA^[a](#tfn5-mmr-19-01-0345){ref-type="table-fn"}^                                                                                        
  ------------------------------------------------------------ ---------------------- -------------------- ------------------ ------------------ ------------------
  *MYCN*^[b](#tfn6-mmr-19-01-0345){ref-type="table-fn"}^       34.84±0.19/0.073       26.41±0.19/8.75      28.79±0.22/1.99    29.22±0.32/2.39    27.66±0.08/4.66
  B-*myb*                                                      28.94±0.27/4.38        27.19±0.26/5.10      28.07±0.91/3.27    27.93±0.31/5.86    27.82±0.05/4.17
  *HPRT1*                                                      31.07±0.13/1.00        29.54±0.32/1.00      29.78±0.05/1.00    30.48±0.15/1.00    29.88±0.11/1.00
  *E2F1*                                                       32.88±0.02/0.29        30.13±0.12/0.66      31.05±0.03/0.41    30.07±0.83/1.33    30.48±1.03/0.66
  *hCdt1*                                                      31.97±0.14/0.54        29.95±0.36/0.75      30.40±0.36/0.65    30.95±0.05/0.72    30.54±0.06/0.63
  *GMNN*^[c](#tfn6-mmr-19-01-0345){ref-type="table-fn"}^       33.09±0.08/0.25        29.37±0.23/1.13      30.35±0.46/0.67    32.96±0.31/0.18    30.84±0.14/0.51
  *p27*                                                        33.64±0.38/0.17        29.97±0.51/0.74      32.39±0.20/0.16    31.89±0.30/0.38    30.73±0.41/0.55
  *CDK2*                                                       32.32±0.21/0.42        30.89±0.70/0.39      32.42±0.55/0.16    32.31±0.46/0.28    31.12±0.12/0.42
  *p21*                                                        34.87±0.07/0.072       32.35±0.56/0.14      35.40±0.02/0.020   37.86±0.22/0.006   32.26±0.09/0.19
  *L3MBTL1*                                                    38.83±1.16/0.005       34.99±0.71/0.023     35.17±1.61/0.024   37.17±0.81/0.010   34.52±1.29/0.040
  c-*myb*^[b](#tfn6-mmr-19-01-0345){ref-type="table-fn"}^      37.54±0.85/0.011       34.59±0.84/0.030     37.18±1.08/0.006   37.18±0.20/0.010   36.11±0.12/0.013
  A-*myb*                                                      0.00                   0.00                 0.00               0.00               0.00
  *E2F2*                                                       0.00                   0.00                 0.00               0.00               0.00
  *p53*                                                        0.00                   0.00                 0.00               0.00               0.00
                                                                                                                                                 
  **B, DNA^[d](#tfn7-mmr-19-01-0345){ref-type="table-fn"}^**                                                                                     
                                                                                                                                                 
                                                               **Cell line (Cp/R)**                                                              
                                                                                                                                                 
  **Gene**                                                     **SH-SY5Y**            **Kelly**            **SIMA**           **MHH-NB-11**      **IMR32**
                                                                                                                                                 
  *MYCN*^[c](#tfn6-mmr-19-01-0345){ref-type="table-fn"}^       29.44±0.13/0.63        22.15±0.56/1488.87   24.77±0.29/80.45   23.89±0.66/74.54   24.99±0.57/82.14
  *p53*                                                        28.78±0.61/1.0         32.69±0.60/1.0       31.10±0.47/1.0     30.11±0.80/1.0     31.35±0.58/1.0

Data (mRNA) are expressed as mean Cp ± standard error of duplicate or triplicate independent experiments in case of discordant results.

Pearson\'s correlation coefficients (*r*=0.88, P\<0.05; *r*=0.86, P=0.059), respectively.

The *MYCN* DNA copy number of *MYCN*-amplified cell lines was calculated from mean Cp ± standard error of the mean of ≥6 independent experiments. Using mean Cp values from quantitative polymerase chain reaction, mRNA expression and DNA copy number were determined using the ∆Cp method. *MYCN, MYCN proto-oncogene bHLH transcription factor*; B-*myb, MYB proto-oncogene like 2*; *HPRT1, hypoxanthine phosphoribosyltransferase* 1; *E2F1, E2F transcription factor 1*; *hCdt1, chromatin licensing and DNA replication factor 1*; *GMNN, geminin*; *p27, cyclin-dependent kinase inhibitor 1B*; *CDK2, cyclin dependent kinase 2*; *p21, cyclin-dependent kinase inhibitor 1A*; *L3MBTL1, L3MBTL1 histone methyl-lysine binding protein*; *c-Myb, transcriptional activator Myb*; A-*myb, MYB proto-oncogene like 1*; *E2F2, E2F transcription factor 2*.
